To the surprise of very few, the state Supreme Court declined to take a look at the court ruling that cleared as legal the California Institute for Regenerative Medicine (CIRM), set up after voters in 2004 approved a $4 billion ballot measure for stem cell research known as Proposition 71, and the dispute apparently is dead. (BioWorld Today)
Bad news from the FDA for Dendreon Corp. on Provenge for prostate cancer sent the firm's stock into a tailspin and trimmed other cancer-vaccine companies' shares as well, taking away some of the gains made when an advisory panel gave the compound a positive vote in late March. (BioWorld Today)
